#PRTG

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem AlphaTON Capital Corp (formerly Portage Biotech) announced a strategic transformation to become a specialized digital asset treasury company focused on the TON blockchain and Telegram ecosystem. The company appointed Brittany Kaiser as CEO and will trade under the new ticker "ATON" starting September 4, 2025.The company secured $38.2 million through private placement and a $35 million loan facility from BitGo Prime to acquire approximately $100 million worth of TON tokens. The strategy includes building a TON treasury, implementing yield generation through validation and staking, and developing ecosystem projects within Telegram's billion-user platform.Strategic partnerships include notable firms like BitGo, Animoca Brands, and SkyBridge, with advisors including Anthony Scaramucci and Michael Terpin.

6 months ago

#PRTG #ATON AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

www.stocktitan.net/news/PRTG/alpha-ton-capi...

0 0 0 0

Die Tech Recruiter

@dietechrecruiter.bsky.social

6 months ago

#Systemadministrator #InfrastructureEngineer #WindowsServer #ActiveDirectory #AzureAD #EntraID #Microsoft365 #ExchangeOnline #Intune #VMware #HyperV #PowerShell #Veeam #PRTG #SCOM #ITJobs #HamburgJobs #BremenJobs #Festanstellung #HybridIdentity

dietechrecruiter.de/jobs/it-admi...

0 0 0 0

Die Tech Recruiter

@dietechrecruiter.bsky.social

6 months ago

#Systemadministrator #InfrastructureEngineer #WindowsServer #ActiveDirectory #AzureAD #EntraID #Microsoft365 #ExchangeOnline #Intune #VMware #HyperV #PowerShell #Veeam #PRTG #SCOM #ITJobs #HamburgJobs #BremenJobs #Festanstellung #HybridIdentity
dietechrecruiter.de/jobs/it-admi...

0 0 0 0

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 Portage Biotech (NASDAQ: PRTG), a clinical-stage immuno-oncology company, reported financial results for fiscal year 2025 ended March 31. The company recorded a net loss of $6.8 million, significantly improved from the $75.4 million loss in FY2024. Operating expenses decreased substantially, with R&D costs dropping 75% to $3.1 million and G&A expenses declining 24.9% to $4.3 million.The company's improved financial performance was primarily due to reduced clinical trial activities, lower non-cash expenses, and decreased operational costs. As of March 31, 2025, Portage maintained cash and cash equivalents of $1.7 million against current liabilities of $1.1 million. The company resumed enrollment in the PORT-6 trial's final dose escalation cohort in March 2025 after a temporary pause in August 2024.

7 months ago

#PRTG Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Liam of the Jungle

@tigger1962.bsky.social

8 months ago

given up using #PRTG for a similar reason... they have jumped on the Broadcom model with pricing to match.

2 0 0 0

Portage Biotech Clears All Nasdaq Listing Requirements, Confirms Market Position Portage Biotech receives official confirmation of meeting all Nasdaq Capital Market listing standards. Get the latest on their compliance status and market position.

8 months ago

#PRTG Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Portage Biotech and Compedica Stock-for-Stock Exchange Portage Biotech (NASDAQ: PRTG) has entered into a stock-for-stock exchange agreement with Compedica Holdings Limited. Portage issued 625,000 shares at $8.00 per share in exchange for 1,165,501 Compedica shares valued at $4.29 each, in a $5 million transaction. Compedica will own 27.4% of Portage's outstanding shares post-transaction. The agreement includes a commitment from Portage to invest at least 50% of future equity funding into Compedica shares at $4.29 per share. Compedica is developing the OptiPulse medical device for diabetic foot ulcers (DFU), targeting a $4+ billion US market. The company expects to publish clinical trial results in Q4 2025 and launch commercial sales in H1 2026. The strategic alliance aims to address the significant unmet need in DFU treatment, which affects 18.6 million people worldwide with a 30% five-year mortality rate.

9 months ago

#PRTG Portage Biotech and Compedica Stock-for-Stock Exchange

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 Portage Biotech (NASDAQ: PRTG) has reported positive preclinical efficacy data for PORT-7, their selective adenosine A2B receptor inhibitor, in mesothelioma treatment. The data will be presented at the AACR Annual Meeting on April 28, 2025, in Chicago.Key findings from the murine mesothelioma model showed that PORT-7 demonstrated superior single-agent activity compared to anti-PD1 antibody treatment. The combination of PORT-7 and anti-PD1 proved more effective than either treatment alone, showing formation of tertiary lymphoid structures and increased immune effector cells.The company is preparing to initiate a first-in-human clinical trial with PORT-7. Additionally, Portage is advancing the dose escalation of PORT-6, their A2A adenosine receptor inhibitor, with plans to co-administer both drugs in the ongoing ADPORT-601 trial, marking the first combination of selective A2A and A2B antagonists in patients.

10 months ago

#PRTG Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Trump

@trump.activitypub.awakari.com.ap.brid.gy

11 months ago

Original post on winsysadminblog.com

Enable SNMP for PRTG with PowerShell An MSP I do some consulting for use PRTG for their monitorin […]

[Original post on winsysadminblog.com]

0 1 0 0

StockQuakes Team

@stockquakes.com

11 months ago

#trading #stock #AI #news #PRTG

Friday March 28, 2025

Even in a down market like today, there are exceptions such as $PRTG, Portage Biotech Inc. with a HUGE StockQuakes UP level of 19.6.

See StockQuakes.com

1 0 0 0

11 months ago

News; ( NASDAQ: #PRTG ) Top Stocks in the News LXRX, SYTA, DBVT, WIMI, MLGO, and PRTG

0 0 0 0

11 months ago

NEWS: ( NASDAQ: #PRTG ) Portage Biotech's PORT-7 Shines in Preclinical Mesothelioma Fight, Eyes Human Trials

0 0 0 0

Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study Revolutionary cancer drug PORT-7 demonstrates powerful anti-tumor activity in mesothelioma, advancing to human trials. Dual-drug strategy shows exceptional promise.

11 months ago

#PRTG Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase Groundbreaking adenosine antagonist therapy advances as PORT-6 reaches final cohort, paving way for first-ever A2A/A2B combination treatment in cancer patients.

1 year ago

#PRTG Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status Portage Biotech receives extended deadline to June 2025 to meet Nasdaq's continued listing criteria, with three compliance pathways available.

1 year ago

#PRTG Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement Immuno-oncology company Portage Biotech raises $2.15M through private placement at $4.10/share, with directors demonstrating confidence through direct investment at market price.

1 year ago

#PRTG Portage Biotech Announces Completion of $2.15 Million Private Financing

www.stocktitan.net/news/PRTG/portage-biotec...

0 0 0 0

StockQuakes Team

@stockquakes.com

1 year ago

#trading #stocks

Big day for the following stocks:

#NUKK Nukkleus Inc.

#PRTG Portage Biotech Inc.

#QUBT Quantum Computing Inc.

#SIDU Sidus Space Inc.

See stockquakes.substack.com for more.

1 0 0 0

Sandy Glass

@skooby.bsky.social

1 year ago

#PRTG is a beast. Been running all day. Up Down. Halts. In and out 5 times now. At one time reaching a high of 12.89. Love me some micro floats. Try my free micro list pinned to my account. Trumpies I charge for it. Here at BlueSky, you get it for free. #daytrading #Stockmarket #microlist

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #PRTG ) Space Invaders

#StockMarket #News

0 0 0 0

1 year ago

Just In: ( NASDAQ: #PRTG ) Portage Biotech Enters LOI with Immunova for an Option to Acquire iOx Therapeutics

#StockMarket #News

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #PRTG ) Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

#StockMarket #News

0 0 0 0

Sandy Glass

@skooby.bsky.social

1 year ago

#PRTG Still going, Micro float runner this mornin. 808.43K float. Boom on news at 7:00 Road it 4.00 to 8.00. Nice since nothing from my microlist ran yesterday. Microlist is pinned to my account and its free. Try it and tell me how you did. #daytrading #stockmarket #microfloat

0 0 1 0